Our strategic approach to SARS-CoV-2 involves the development of AV-001 for treating patients with severe COVID-19 disease and vaccines to prevent infection businesswire.com/news/home/2021…

Vasomune Therapeutics doses first patient in Phase 2a clinical study to evaluate AV-001 in patients hospitalized with severe COVID-19 disease. businesswire.com/news/home/2022…

We are pleased to announce that the Independent Data and Safety Monitoring Board recommended the continuation of the Phase 2a trial (NCT05123755) evaluating the efficacy, safety, and tolerability of AV-001 in patients suffering with Acute Respiratory... businesswire.com/news/home/2023…

On May 21, 2024, Vasomune's Dr. Harold Kim will present Phase 1 safety, and pharmacokinetic and pharmacodynamic data for AV-001 as a late-breaking scientific poster at the American Thoracic Society Clinical and Scientific sessions. lnkd.in/gYM4HPAk

Vasomune Therapeutics Receives US FDA Fast Track Designation for Novel Investigational Medicine AV-001 businesswire.com/news/home/2024…

Congratulations to biopharmaceutical company Vasomune Therapeutics, Inc. for receiving Fast Track designation by the U.S. FDA for investigational medicine AV-001, which aims to address (and prevent) acute respiratory distress syndrome (ARDS).

On Monday, June 5th at 3pm PST, Dr Brian Jahns presents the Vasomune Therapeutics story. Join Brian in Theatre 3 for the story of how Vasomune achieved the Fast Track Designation for pneumonia ARDS, and what his vision for the future is. convention.bio.org/sessions/vasom…

This week AstraZeneca completed the acquisition of Genesys portfolio company Fusion Pharmaceuticals for US$2.4B! What a journey it has and we're thrilled to see Ontario becoming a global hub of excellence for radiopharmaceuticals. prnewswire.com/news-releases/…

These five startups are working on solutions that could speed up diagnosis, develop promising new therapeutics and improve patient care. Check them out at #MaRSImpactHealth happening June 12 and 13. marsdd.com/news/meet-5-en…

Ft. Beth Rogozinski (CEO of Oncoustics Inc.), Alison Smith (co-founder and chief scientist at Roga), Felix Baldauf-Lenschen (CEO of Altis Labs), Adam Forman (co-founder of Synakis) and Brian Jahns (COO of Vasomune Therapeutics, Inc.).

👏🏽Congratulations to Vasomune Therapeutics, Inc. on this milestone! We are proud of #OBIO member, Vasomune, as they receive U.S. FDA Fast Track Designation for AV-001. Looking forward to seeing you advance to the next phase!

MHSRS-24-11804 (Full title in article) at 2024 Military Health System Research Symposium. Read more in the link below. linkedin.com/feed/update/ur…

Thank you ARDSALLiance and Paula Blonski for striving against ARDS, and for reminding us why continued research into prevention and treatment is so important. linkedin.com/posts/paulablo…

Vasomune Therapeutics, Inc. is proud to be in Florida presenting our work at the 2024 Military Health System Research Symposium! With their support we have come a long way from preclinical to Phase 2a with AV-001 for the prevention and treatment of ARDS. linkedin.com/posts/haroldki…

🧬Next up as part of our #GlobalBiotechWeek celebration is Vasomune Therapeutics, Inc. who reached the milestone of receiving U.S. FDA Fast Track Designation for their novel investigational medicine AV-001. 👏🏽 We're proud of Vasomune, an #OBIO member, as they continue to advance to the next phase!

Health Canada approves a new trial for Pegevongitide (AV-001) — a made-in-Canada therapy co-developed by Vasomune & AnGes — to protect hemodialysis patients from brain injury by stabilizing the cerebrovasculature.